The management of severe community acquired pneumonia in the intensive care unit

References

• Marcos I, Restrepo MD. Antonio Anzueto. Severe community – acquired pneumonia. Infect Dis Clin N Am 2009;23(3):503-20
   Google Scholar
• Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community acquired pneumonia in adults. Clin Infect Dis 2007;44(Suppl 2):S27-72
   PubMed Web of Science ®Google Scholar
• Woodhead M, Welch CA, Harrison DA, et al. Community-acquired pneumonia on the intensive care unit: secondary analysis of 17,869 cases in the ICNARC Case Mix Programme Database. Crit Care 2006;10(Suppl 2):S1
   PubMedGoogle Scholar
• Griffin MR, Zhu Y, Moore MR, et al. U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination. N Engl J Med 2013;369(2):155-63
   PubMed Web of Science ®Google Scholar
• Corrales-Medina VF, Musher DM, Wells GA, et al. Cardiac complications in patients with community-acquired pneumonia: incidence, timing, risk factors, and association with short-term mortality. Circulation 2012;125(6):773-81
   PubMed Web of Science ®Google Scholar
• Restrepo MI, Mortensen EM, Rello J, et al. Late admission to the ICU in patients with community-acquired pneumonia is associated with higher mortality. Chest 2010;137(3):552-7
   PubMed Web of Science ®Google Scholar
• Leroy O, Santre C, Beuscart C, et al. A five-year study of severe community-acquired pneumonia with emphasis on prognosis in patients admitted to an intensive care unit. Intensive Care Med 1995;21(1):24-31
   PubMed Web of Science ®Google Scholar
• Marti C, Garin N, Grosgurin O, et al. Prediction of severe community-acquired pneumonia: a systematic review and meta-analysis. Crit Care 2012;16(4):R141
   PubMed Web of Science ®Google Scholar
• Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign guidelines committee including the pediatric subgroup. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 2013;39(2):165-228
   PubMed Web of Science ®Google Scholar
• Septic shock: the initial moments and beyond. Available from: www.ccjm.org/content/80/3/175.full
   Google Scholar
• Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997;336(4):243-50
   PubMed Web of Science ®Google Scholar
• Barlow G, Nathwani D, Davey P. The CURB65 pneumonia severity score outperforms generic sepsis and early warning scores in predicting mortality in community-acquired pneumonia. Thorax 2007;62(3):253-9
   PubMed Web of Science ®Google Scholar
• Liapikou A, Ferrer M, Polverino E, et al. Severe community-acquired pneumonia: validation of the Infectious Diseases Society of America/American Thoracic Society guidelines to predict an intensive care unit admission. Clin Infect Dis 2009;48(4):377-85
   PubMed Web of Science ®Google Scholar
• Charles PG, Wolfe R, Whitby M, et al. Australian Community-Acquired Pneumonia Study Collaboration. SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin Infect Dis 2008;47(3):375-84
   PubMed Web of Science ®Google Scholar
• Renaud B, Santin A, Coma E, et al. Association between timing of intensive care unit admission and outcomes for emergency department patients with community-acquired pneumonia. Crit Care Med 2009;37(11):2867-74
   PubMed Web of Science ®Google Scholar
• España PP, Capelastegui A, Quintana JM, et al. Validation and comparison of SCAP as a predictive score for identifying low-risk patients in community-acquired pneumonia. J Infect 2010;60(2):106-13
   Google Scholar
• Woodhead M, Blasi F, Ewig S, et al. Joint Taskforce of the European Respiratory Society and European Society for Clinical Microbiology and Infectious Diseases Guidelines for the management of adult lower respiratory tract infections. Clin Microbiol Infect 2011;17(Suppl 6):E1-E59
   Google Scholar
• Ramírez P, Ferrer M, Martí V, et al. Inflammatory biomarkers and prediction for intensive care unit admission in severe community-acquired pneumonia. Crit Care Med 2011;39(10):2211-17
   PubMed Web of Science ®Google Scholar
• Menendez R, Martinez R, Reyes S, et al. Biomarkers improve mortality prediction by prognostic scales in community-acquired pneumonia. Thorax 2009;64(7):587-91
   PubMed Web of Science ®Google Scholar
• Falguera M, Carratalà J, Ruiz-Gonzalez A, et al. Risk factors and outcome of community-acquired pneumonia due to Gram-negative bacilli. Respirology 2009;14(1):105-11
   PubMed Web of Science ®Google Scholar
• Choi SH, Hong SB, Ko GB, et al. Viral infection in patients with severe pneumonia requiring intensive care unit admission. Am J Respir Crit Care Med 2012;186(4):325-32
   PubMed Web of Science ®Google Scholar
• Cillóniz C, Ewing S, Polverino E, et al. Microbial etiology of community-acquired pneumonia and its relation to severity. Thorax 2011;66(4):340-6
   PubMed Web of Science ®Google Scholar
• Wu CL, Ku SC, Yang KY, et al. Antimicrobial drug – resistant microbes associated with hospitalized community – acquired and healthcare – associated pneumonia: a multi-center study in Taiwan. J Formos Med Assoc 2013;112(1):31-40
   Google Scholar
• Schreiber MP, Chan CM, Shorr AF. Resistant pathogens in non – nosocomial pneumonia and respiratory failure: is it time to refine the definition of health-care-associated pneumonia? Chest 2010;137(6):1283-8
   PubMed Web of Science ®Google Scholar
• Shorr AF, Zilberberg MD, Reichley R, et al. Validation of a clinical score for assessing the risk of resistant pathogens in patients with pneumonia presenting to the emergency department. Clin Infect Dis 2012;54(2):193-8
   PubMed Web of Science ®Google Scholar
• Aliberti S, Di Pasquale M, Zanaboni AM, et al. Stratifying risk factors for multidrugresistant pathogens in hospitalized patients coming from the community with pneumonia. Clin Infect Dis 2011;54(4):470-8
   Google Scholar
• Surviving sepsis campaign. Available from: www.survivingsepsis.org
   Google Scholar
• McCabe C, Kirchner C, Zhang H, et al. Guideline-concordant therapy and reduced mortality and length of stay in adults with community-acquired pneumonia: playing by the rules. Arch Intern Med 2009;169(16):1525-31
   PubMedGoogle Scholar
• Ferrer R, Artigas A, Levy MM, et al. Improvement in process of care and outcome after a multicenter severe sepsis educational program in Spain. JAMA 2008;299(19):2294-303
   PubMed Web of Science ®Google Scholar
• Levy MM, Dellinger RP, Townsend SR, et al. The Surviving Sepsis Campaign: results of an international guideline based performance improvement program targeting severe sepsis. Crit Care Med 2010;38(2):367-74
   PubMed Web of Science ®Google Scholar
• Paul M, Shani V, Muchtar E, et al. Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis. Antimicrob Agents Chemother 2010;54(11):4851-63
   PubMed Web of Science ®Google Scholar
• Mikkelsen ME, Miltiades AN, Gaieski DF, et al. Serum lactate is associated with mortality in severe sepsis independent of organ failure and shock. Crit Care Med 2009;37(5):1670-7
   PubMed Web of Science ®Google Scholar
• Nguyen HB, Kuan WS, Batech M, et al. Outcome effectiveness of the severe sepsis resuscitation bundle with addition of lactate clearance as a bundle item: a multinational evaluation. Crit Care 2011;15(5):R229
   Google Scholar
• Brunkhorst FM, Engel C, Bloos F, et al. German Competence Network Sepsis (SepNet). Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008;358(2):125-39
   PubMed Web of Science ®Google Scholar
• Delaney AP, Dan A, McCaffrey J, Finfer S. The role of albumin as a resuscitation fluid for patients with sepsis: a systematic review and meta-analysis. Crit Care Med 2011;39(2):386-91
   PubMed Web of Science ®Google Scholar
• Blot SI, Rodriguez A, Solé-Violán J, et al. Community-Acquired Pneumonia Intensive Care Units (CAPUCI) Study Investigators. Effects of delayed oxygenation assessment on time to antibiotic delivery and mortality in patients with severe community-acquired pneumonia. Crit Care Med 2007;35(11):2509-14
   PubMed Web of Science ®Google Scholar
• Wiener RS, Wiener DC, Larson RJ. Benefits and risks of tight glucose control in critically ill adults: a meta-analysis. JAMA 2008;300(8):933-44
   PubMed Web of Science ®Google Scholar
• Menéndez R, Torres A, Reyes S, et al. Initial management of pneumonia and sepsis: factors associated with improved outcome. Eur Respir J 2012;39(1):156-62
   PubMed Web of Science ®Google Scholar
• Shorr AF, Bodi M, Rodriguez A, et al. CAPUCI Study Investigators. Impact of antibiotic guideline compliance on duration of mechanical ventilation in critically ill patients with community-acquired pneumonia. Chest 2006;130(1):93-100
   PubMed Web of Science ®Google Scholar
• Kumar A, Ellis P, Arabi Y, et al. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest 2009;136(5):1237-48
   PubMed Web of Science ®Google Scholar
• Rodriguez A, Mendia A, Sirvent JM, et al. Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock. Crit Care Med 2007;35(6):1493-8
   PubMed Web of Science ®Google Scholar
• Leroy O, Saux P, Bédos JP, Caulin E. Comparison of levofloxacin and cefotaxime combined with ofloxacin for ICU patients with community-acquired pneumonia who do not require vasopressors. Chest 2005;128(1):172-83
   PubMed Web of Science ®Google Scholar
• Diaz-Martin A, Martinez-Gonzalez ML, Ferrer R, et al. the Edusepsis Study Group. Antibiotic prescription patterns in the empirical therapy of severe sepsis: combination of antimicrobials with different mechanisms of action reduce mortality. Crit Care 2012;16(6):R223
   PubMed Web of Science ®Google Scholar
• Martínez JA, Horcajada JP, Almela M, et al. Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2003;36(4):389-95
   PubMed Web of Science ®Google Scholar
• Baddour LM, Yu VL, Klugman KP, et al. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med 2004;170(4):440-4
   PubMed Web of Science ®Google Scholar
• Martin-Loeches I, Lisboa T, Rodriguez A, et al. Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia. Intensive Care Med 2010;36(4):612-20
   PubMed Web of Science ®Google Scholar
• Restrepo MI, Mortensen EM, Waterer GW, et al. Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia. Eur Respir J 2009;33(1):153-9
   PubMed Web of Science ®Google Scholar
• Lodise TP, Kwa A, Cosler L, et al. Comparison of beta-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia. Antimicrob Agents Chemother 2007;51(11):3977-82
   PubMed Web of Science ®Google Scholar
• Hyvernat H, Pulcini C, Carles D, et al. Fatal Staphylococcus aureus hemorrhagic pneumonia producing Panton-Valentine leucocidin. Scand J Infect Dis 2007;39(2):183-5
   PubMed Web of Science ®Google Scholar
• Bautista E, Chotpitayasunondh T, Gao Z, et al. Writing Committee of the WHO Consultation on Clinical Aspects of Pandemic (H1N1) 2009 Influenza, Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med 2010;362(18):1708-19
   Google Scholar
• Sprung CL, Annane D, Keh D, et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008;358(2):111-24
   PubMed Web of Science ®Google Scholar
• Annane D, Sébille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002;288(7):862-71
   PubMed Web of Science ®Google Scholar
• Confalonieri M, Urbino R, Potena A, et al. Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med 2005;171(3):242-8
   PubMed Web of Science ®Google Scholar
• Snijders D, Daniels JM, de Graaff CS, et al. Efficacy of corticosteroids in community-acquired pneumonia: a randomized double-blinded clinical trial. Am J Respir Crit Care Med 2010;181(9):975-82
   PubMed Web of Science ®Google Scholar
• Sibila O, Agusti C, Torres A. Corticosteroids in severe pneumonia. Eur Respir J 2008;32:259-64
   PubMed Web of Science ®Google Scholar
• Confalonieri M, Annane D, Antonaglia C, et al. Is prolonged low-dose glucocorticoid treatment beneficial in community-acquired pneumonia. Curr Infect Dis Rep 2013;15(2):158-66
   PubMedGoogle Scholar
• Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med 2013;369(9):840-51
   PubMed Web of Science ®Google Scholar
• Bouadma L, Luyt CE, Tubach F, et al. PRORATA trial group. Use of procalcitonin to reduce patients’ exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomized controlled trial. Lancet 2010;375(9713):463-74
   PubMed Web of Science ®Google Scholar
• Schuetz P, Maurer P, Punjabi V, et al. Procalcitonin decrease over 72 hours in US critical care units predicts fatal outcome in sepsis patients. Crit Care 2013;17(3):R115
   PubMed Web of Science ®Google Scholar
• Keh D, Boenhke T, Weber-Cartens S, et al. Immunologic and hemodynamic effects of ‘‘low-dose’’ hydrocortisone in septic shock. A double blind, randomized, placebo – controlled, crossover study. Am J Respir Crit Care Med 2003;167(4):512-20
   PubMed Web of Science ®Google Scholar
• Laupland KB, Kirkpatrick AW, Delaney A. Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: a systematic review and meta-analysis. Crit Care Med 2007;35(12):2686-92
   Google Scholar
• Kreymann KG, de Heer G, Nierhaus A, Kluge S. Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock. Crit Care Med 2007;35(12):2677-85
   PubMed Web of Science ®Google Scholar
• Wise MP, Williams DW, Lewis MA, Frost PJ. Macrolides and community-acquired pneumonia: is quorum sensing the key? Crit Care 2010;14(4):181
   Google Scholar
• Giamarellos-Bourboulis EJ, Raftogiannis M. The immune response to severe bacterial infections: consequences for therapy. Expert Rev Anti Infect Ther 2012;10(3):369-80
   PubMed Web of Science ®Google Scholar
• Khan AR, Riaz M, Bin Abdulhak AA, et al. The role of statins in prevention and treatment of community acquired pneumonia: a systematic review and meta-analysis. PLoS One 2013;8(1):e52929
   PubMed Web of Science ®Google Scholar
• Yende S, Milbrandt EB, Kellum JA, et al. Understanding the potential role of statins in pneumonia and sepsis. Crit Care Med 2011;39(8):1871-8
   PubMedGoogle Scholar
• http://content.yudu.com/Library/A2fush/HospitalInfectiousDi/resources/44.htm
   Google Scholar
• Roche Molecular Diagnostics. SeptiFast: the impact of rapid results. Available from: http://molecular.roche.com/commonfiles/media/pdf/51_septifast.pdf [Last accessed 10 June 2010]
   Google Scholar
• Kerschen EJ, Fernandez JA, Cooley BC, et al. Endotoxemia and sepsis mortality reduction by non-anticoagulant activated protein C. J Exp Med 2007;204(2):2439-48
   Google Scholar
• Yang RB, Mark MR, Gray A, et al. Toll-like receptor-2 mediates lipopolysaccharide – induced cellular signalling. Nature 1998;395(6699):284-8
   PubMed Web of Science ®Google Scholar
• Wong HR. Clinical review: sepsis and septic shock — the potential of gene arrays. Crit Care 2012;16(1):204
   PubMed Web of Science ®Google Scholar